Houda Boukhebza, et al. Vaccine. 2014, 32(26):3256-63. – Download the article Publication
Category: Publication
Combination of the oncolytic vaccinia virus TG6002 with conventional chemotherapeutic agents in human tumor models resistant to viral oncolysis.
Johann Foloppe, et al. 8th International Conference on Oncolytic Virus Therapeutics. 10-13 April 2014, Oxford, United Kingdom, Abst. 64 Download the poster here Poster Presentation
Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein.
Christelle Remy-Ziller, et al. Clinical and vaccine immunology. 2014; 21(2): 147-155 – Download the article Publication
Immunotherapy for non – small – cell lung cancer: current approaches.
Elisabeth Quoix, et al. Current Respiratory Care Reports, 2014; 3 (1): 19-25 – Download the article Publication
Preclinical evaluation of MVA-MUC1-IL2 in combination with chemotherapy in murine models.
Micaël De Meyer, et al. Journal for Immunotherapy of Cancer, 2013 – Download the article Publication
TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.
Perrine Martin, et al. Hepatology, 2013, (58) S1, 222A–225A – Download the article Publication
Pre-clinical proof-of-concept studies exploring schedules of administration of an adenovirus-based HBV immunotherapeutic show wide potential for induction of robust and long-lasting T-cell responses.
Houda Boukhebza, et al. Journal of Hepatology, 2013, (58), Supplement 1, S161 – Download the article Publication
130 – A multivalent adenovirus-based immunotherapeutic for treatment of chronic hepatitis B induces broad, robust and polyfunctional T cells in naive and HBV tolerant mice.
Perrine Martin, et al. Journal of Hepatology, 2013, (58), Supplement 1, S57–S58. – Download the article Publication
Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)
link J. Heo, C. Breitbach, M. Cho, T.H. Hwang, C.W. Kim, U.B. Jeon, H.Y. Woo, K.T. Yoon, J.W. Lee, J. Burke, T. Hickman, K. Dubois, L. Longpre, R. Patt, D.H. Kirn Journal of clinical Oncology, 2013, 31, (suppl; abstr 4122) [Publication]
Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)
link J. Lee J, S.Y. Park, J. Burke, H.Y. Lim, J. Lee, W.K. Kang, J.O. Park, A. Pelusio, C. Breitbach, D.H. Kirn Journal of clinical Oncology, 2013, 31, (suppl; abstr 3608) [Publication]
